Target type: biologicalprocess
The process in which immune receptor V, D, and J, or V and J gene segments, depending on the specific receptor, are recombined within a single locus utilizing the conserved heptamer and nonomer recombination signal sequences (RSS). [GOC:add, ISBN:0781700221, ISBN:0781735149]
V(D)J recombination is a critical process in the development of a functional immune system. It occurs in developing lymphocytes, specifically B cells and T cells, and is responsible for generating the vast diversity of antigen receptors, known as immunoglobulins (antibodies) in B cells and T cell receptors (TCRs) in T cells. This diversity is essential for the immune system to recognize and respond to a wide range of pathogens.
The process involves the rearrangement of gene segments called variable (V), diversity (D), and joining (J) segments. These segments are located in different loci on the genome: the V locus, the D locus (only present in the immunoglobulin heavy chain and TCR beta chain), and the J locus.
Here is a step-by-step breakdown of V(D)J recombination:
1. **DNA Cleavage:** The first step is the precise cleavage of DNA at the junctions between the V, D, and J segments. This cleavage is mediated by a specialized enzyme complex called the V(D)J recombinase, which consists of two key proteins: RAG1 and RAG2. RAG1 recognizes and binds to specific DNA sequences called recombination signal sequences (RSSs) flanking the V, D, and J segments. RAG2 then assists RAG1 in creating double-stranded breaks in the DNA.
2. **Hairpin Formation:** After cleavage, the broken DNA ends form hairpin structures. These hairpins are important for ensuring that the correct segments are joined together.
3. **Exonucleolytic Processing:** The hairpin structures are then processed by exonucleases, which remove nucleotides from the ends of the DNA. This processing can lead to the loss of nucleotides, resulting in deletions and variations in the sequence of the rearranged gene.
4. **Nucleotide Addition:** Once the hairpins have been processed, terminal deoxynucleotidyl transferase (TdT) can add non-templated nucleotides (N-nucleotides) to the ends of the DNA. This addition of N-nucleotides further contributes to the diversity of the rearranged gene.
5. **Joining:** The processed DNA ends are then joined together by the enzyme DNA ligase IV. This step completes the rearrangement of the V, D, and J segments, generating a functional VDJ exon.
6. **Transcription and Translation:** The rearranged gene is transcribed into messenger RNA (mRNA) and translated into a protein, which forms part of the antigen receptor.
V(D)J recombination is a highly regulated process that involves several factors, including:
* **Specificity of Recombination:** The process is highly specific, ensuring that only the correct V, D, and J segments are joined together. This specificity is mediated by the RSSs flanking each segment.
* **Accessibility of DNA:** The accessibility of the DNA in the V, D, and J loci is regulated by chromatin modifications, which control the packaging and accessibility of DNA.
* **Timing and Location:** V(D)J recombination occurs at specific stages of lymphocyte development and in specific locations within the cell.
Errors in V(D)J recombination can lead to a variety of immune disorders, including immunodeficiency and autoimmunity. These errors can arise from defects in the recombinase complex or other factors involved in the process.
In summary, V(D)J recombination is a complex and tightly regulated process that generates the vast diversity of antigen receptors required for an effective adaptive immune response. It is essential for the immune system to recognize and respond to a wide range of pathogens and for maintaining immune homeostasis.'
"
Protein | Definition | Taxonomy |
---|---|---|
Serine-protein kinase ATM | A serine-protein kinase ATM that is encoded in the genome of human. [PRO:CNA] | Homo sapiens (human) |
DNA ligase 1 | A DNA ligase 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P18858] | Homo sapiens (human) |
High mobility group protein B1 | A high mobility group protein B1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P09429] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
salicylic acid | Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL). | monohydroxybenzoic acid | algal metabolite; antifungal agent; antiinfective agent; EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor; keratolytic drug; plant hormone; plant metabolite |
pd 173074 | aromatic amine; biaryl; dimethoxybenzene; pyridopyrimidine; tertiary amino compound; ureas | antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist | |
caffeine | purine alkaloid; trimethylxanthine | adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic | |
chloroquine | chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis. Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses. | aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound | anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug |
diflunisal | diflunisal : An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position. Diflunisal: A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN. | monohydroxybenzoic acid; organofluorine compound | non-narcotic analgesic; non-steroidal anti-inflammatory drug |
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source | chromones; morpholines; organochlorine compound | autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector |
glycyrrhizic acid | glycyrrhizinic acid : A triterpenoid saponin that is the glucosiduronide derivative of 3beta-hydroxy-11-oxoolean-12-en-30-oic acid. | enone; glucosiduronic acid; pentacyclic triterpenoid; tricarboxylic acid; triterpenoid saponin | EC 3.4.21.5 (thrombin) inhibitor; plant metabolite |
schizandrin b | schizandrin B: a phytogenic antineoplastic agent with anti-inflammatory activity; isolated from Schisandra plant | ||
methotrexate | dicarboxylic acid; monocarboxylic acid amide; pteridines | abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent | |
thiourea | thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur. Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS. | one-carbon compound; thioureas; ureas | antioxidant; chromophore |
ku 55933 | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one: specific inhibitor of the ataxia-telangiectasia mutated kinase ATM; structure in first source | ||
cgk 733 | diarylmethane | ||
nu 7026 | 2-(morpholin-4-yl)benzo(h)chromen-4-one: a radiosensitizing agent that inhibits DNA-dependent protein kinase; structure in first source | organic heterotricyclic compound; organooxygen compound | |
ol-135 | |||
nu 7441 | 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one: structure in first source | dibenzothiophenes | |
ku-0060648 | dibenzothiophenes | ||
dactolisib | dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment. dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR | imidazoquinoline; nitrile; quinolines; ring assembly; ureas | antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor |
ku 60019 | |||
cp 466722 | quinazolines | ||
(3R)-4-[2-(1H-indol-4-yl)-6-(1-methylsulfonylcyclopropyl)-4-pyrimidinyl]-3-methylmorpholine | indoles | ||
ve 821 | 3-amino-6-(4-(methylsulfonyl)phenyl)-N-phenylpyrazine-2-carboxamide: an antineoplastic agent; structure in first source | aromatic amide | |
torin 2 | torin 2 : A member of the class of pyridoquinolines that is benzo[h][1,6]naphthyridin-2-one carrying additional 3-(trifluoromethyl)phenyl and 6-aminopyridin-3-yl substituents at positions 1 and 9 respectively. It is a potent inhibitor of mTOR and exhibits anti-cancer properties. | aminopyridine; organofluorine compound; primary amino compound; pyridoquinoline | antineoplastic agent; mTOR inhibitor |
byl719 | proline derivative | ||
cc-115 | 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1H)-one: an mTOR kinase inhibitor; structure in first source | ||
vx-970 | berzosertib: an ATR kinase inhibitor | sulfonamide | |
etp-46464 | ETP-46464: inhibits ATM and Rad3-related kinase; structure in first source |